Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TDP1 | Q9NUW8 | 5/20 | 0.70 |
| ▸ | MEN1 | O00255 | 1/20 | 0.68 |
| ▸ | ABL1 | P00519 | 1/20 | 0.68 |
| ▸ | LMNA | P02545 | 1/20 | 0.68 |
| ▸ | PKM | P14618 | 1/20 | 0.68 |
| ▸ | IDE | P14735 | 1/20 | 0.68 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.68 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.68 |
| ▸ | RIN1 | Q13671 | 1/20 | 0.68 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.68 |
| ▸ | HLCS | P50747 | 6/20 | 0.65 |
| ▸ | CA12 | O43570 | 6/20 | 0.61 |
| ▸ | CA1 | P00915 | 6/20 | 0.61 |
| ▸ | CA2 | P00918 | 6/20 | 0.61 |
| ▸ | CA9 | Q16790 | 6/20 | 0.61 |
| ▸ | F2 | P00734 | 1/20 | 0.59 |
| ▸ | PRSS1 | P07477 | 1/20 | 0.59 |
| ▸ | PRSS2 | P07478 | 1/20 | 0.59 |
| ▸ | PRSS3 | P35030 | 1/20 | 0.59 |
| ▸ | TPSAB1 | Q15661 | 1/20 | 0.59 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL23126169 | 1.00 | TDP1 (0.70) | TDP1MEN1ABL1LMNAPKM | |
| SCHEMBL10051079 | 1.00 | TDP1 (0.70) | TDP1MEN1ABL1LMNAPKM | |
| SCHEMBL13899175 | 1.00 | TDP1 (0.70) | TDP1MEN1ABL1LMNAPKM | |
| SCHEMBL23126156 | 1.00 | TDP1 (0.70) | TDP1MEN1ABL1LMNAPKM | |
| SCHEMBL19034459 | 1.00 | TDP1 (0.70) | TDP1MEN1ABL1LMNAPKM | |
| SCHEMBL22473615 | 0.99 | TDP1 (0.68) | TDP1MEN1ABL1LMNAPKM | |
| SCHEMBL31677482 | 0.95 | TDP1 (0.66) | TDP1MEN1ABL1LMNAPKM | |
| SCHEMBL14614382 | 0.94 | TDP1 (0.71) | TDP1MEN1ABL1LMNAPKM | |
| SCHEMBL2632289 | 0.94 | TDP1 (0.71) | TDP1MEN1ABL1LMNAPKM | |
| SCHEMBL14274132 | 0.91 | TDP1 (0.60) | TDP1MEN1ABL1LMNAPKM |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 31 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3886579-B2 | EX VIVO ORGAN TREATMENT WITH PEG-PHOSPHOLIPID MOLECULES | ICOAT MEDICAL AB (SE) | 2025-12-24 | — | — | EP | disclosed |
| US-20250177448-A1 | NEW USE OF PEG-PHOSPHOLIPID MOLECULES | ICOAT MEDICAL AB (SE) | 2025-06-05 | — | — | US | disclosed |
| EP-4490272-A1 | NEW USE OF PEG-PHOSPHOLIPID MOLECULES | iCoat Medical AB (SE) | 2025-01-15 | — | — | EP | disclosed |
| CN-118900913-A | New use of PEG-phospholipid molecule | 爱科特医药公司 | 2024-11-05 | — | — | CN | disclosed |
| US-20230365646-A1 | AZIDE INSULIN ANALOGUES | MERCK SHARP & DOHME LLC (US) | 2023-11-16 | — | — | US | disclosed |
| US-20230365646-A1 | AZIDE INSULIN ANALOGUES | MERCK SHARP & DOHME LLC (US) | 2023-11-16 | — | — | US | disclosed |
| WO-2023172180-A1 | NEW USE OF PEG-PHOSPHOLIPID MOLECULES | ICOAT MEDICAL AB (SE) | 2023-09-14 | — | — | WO | disclosed |
| EP-3886579-B1 | EX VIVO ORGAN TREATMENT WITH PEG-PHOSPHOLIPID MOLECULES | ICOAT MEDICAL AB (SE) | 2023-06-07 | — | — | EP | disclosed |
| US-11660290-B2 | Affinity based drug release formulations | MCMASTER UNIVERSITY (CA) | 2023-05-30 | — | — | US | disclosed |
| CN-113056193-B | Ex vivo organ treatment with PEG phospholipid molecules | 爱科特医药公司 | 2022-12-20 | — | — | CN | disclosed |
| US-20170320886-A1 | CORTISTATIN ANALOGUES AND SYNTHESES THEREOF | PRESIDENT AND FELLOWS OF HARVARD COLLEGE (US) | 2017-11-09 | — | — | US | disclosed |
| EP-2531463-B1 | HYPERVALENT RADIOACTIVE ASTATINE OR IODINE COMPOUNDS, AND PREPARATION METHODS THEREOF | INST NAT DE LA SANTE ET DE LA RECH MEDICALE (INSERM) (FR) | 2017-11-01 | — | — | EP | disclosed |
| WO-2017184999-A1 | EZH2 INHIBITORS AND USES THEREOF | DANA-FARBER CANCER INSTITUTE, INC. (US) | 2017-10-26 | — | — | WO | disclosed |
| US-20160169864-A1 | FIBER COATED NANOPORES | NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT | 2016-06-16 | — | — | US | disclosed |
| WO-2016073903-A1 | USE OF COMPOSITIONS MODULATING CHROMATIN STRUCTURE FOR GRAFT VERSUS HOST DISEASE (GVHD) | DANA-FARBER CANCER INSTITUTE, INC. (US) | 2016-05-12 | — | — | WO | disclosed |
| US-9290421-B2 | Hypervalent radioactive astatine or iodine compounds, and preparation methods thereof | Institut National de la Santé de la Recherche Medicalé (FR) | 2016-03-22 | — | — | US | disclosed |
| WO-2013152279-A1 | CHEMOENZYMATIC METHODS FOR SYNTHESIZING MOENOMYCIN ANALOGS | PRESIDENT AND FELLOWS OF HARVARD COLLEGE (US) | 2013-10-10 | — | — | WO | disclosed |
| US-20130004420-A1 | HYPERVALENT RADIOACTIVE ASTATINE OR IODINE COMPOUNDS, AND PREPARATION METHODS THEREOF | UNIVERSITE DE NANTES (FR) | 2013-01-03 | — | — | US | disclosed |
| WO-2011095517-A1 | HYPERVALENT RADIOACTIVE ASTATINE OR IODINE COMPOUNDS, AND PREPARATION METHODS THEREOF | INSTITUT NATIONAL DE LA SANTE ET DE LA RECHERCHE MEDICALE (INSERM) (FR) | 2011-08-11 | — | — | WO | disclosed |
| US-5807879-A | Biotinidase-resistant biotinylated compound and methods of use thereof | UNIVERSITY OF ROCHESTER (US) | 1998-09-15 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230365646-A1 | AZIDE INSULIN ANALOGUES | IAPP, INSR, GPR119 | TDP1 4101/4885MEN1 68/4885ABL1 499/4885 |
| US-20250177448-A1 | NEW USE OF PEG-PHOSPHOLIPID MOLECULES | PLTP, PHOSPHO1, CD47 | TDP1 4628/4885MEN1 2727/4885ABL1 1752/4885 |
| US-11660290-B2 | Affinity based drug release formulations | ABCG2, ABCB1, ABCB11 | TDP1 2465/4885MEN1 2732/4885ABL1 1347/4885 |
| US-20170320886-A1 | CORTISTATIN ANALOGUES AND SYNTHESES THEREOF | CTTN, TEK, FLT1 | TDP1 4363/4885MEN1 110/4885ABL1 1123/4885 |
| US-20130004420-A1 | HYPERVALENT RADIOACTIVE ASTATINE OR IODINE COMPOUNDS, AND PREPARATION METHODS THEREOF | TSHR, SLC7A1, H1-3 | TDP1 1839/4885MEN1 2015/4885ABL1 126/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.